Chlorpromazine

Chlorpromazine

SCHEMBL41771

CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2DRD3DRD4HTR2A

The experimentally established mechanism targets of Chlorpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 5/20 1.00
DRD3 known ✓ P35462 5/20 0.97
DRD4 known ✓ P21917 3/20 0.97
HTR2A known ✓ P28223 3/20 0.97
CYP1A2 P05177 9/20 1.00
CYP2D6 P10635 9/20 1.00
LMNA P02545 6/20 1.00
MAPT P10636 6/20 1.00
HTR1A P08908 6/20 1.00
CYP2C19 P33261 5/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
NPSR1 Q6W5P4 5/20 1.00
PMP22 Q01453 4/20 1.00
TDP1 Q9NUW8 3/20 1.00
MEN1 O00255 3/20 1.00
GMNN O75496 3/20 1.00
KMT2A Q03164 3/20 1.00
KDM4E B2RXH2 2/20 1.00
GFER P55789 2/20 1.00
POLB P06746 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chlorpromazine SCHEMBL8503036 1.00 CYP1A2 (1.00) CYP1A2CYP2D6LMNAMAPTHTR1A
Chlorpromazine SCHEMBL23326209 1.00 CYP1A2 (1.00) CYP1A2CYP2D6LMNAMAPTHTR1A
Chlorpromazine SCHEMBL5483904 1.00 CYP1A2 (1.00) CYP1A2CYP2D6LMNAMAPTHTR1A
Chlorpromazine SCHEMBL29351728 1.00 CYP1A2 (1.00) CYP1A2CYP2D6LMNAMAPTHTR1A
Chlorpromazine SCHEMBL29714121 1.00 CYP1A2 (1.00) CYP1A2CYP2D6LMNAMAPTHTR1A
Chlorpromazine SCHEMBL28234010 0.99 CYP1A2 (0.97) CYP1A2CYP2D6LMNAMAPTHTR1A
Chlorpromazine SCHEMBL29367385 0.99 CYP1A2 (1.00) CYP1A2CYP2D6LMNAMAPTHTR1A
Chlorpromazine SCHEMBL29358018 0.99 CYP1A2 (1.00) CYP1A2CYP2D6LMNAMAPTHTR1A
Chlorpromazine SCHEMBL8321 0.99 CYP1A2 (1.00) CYP1A2CYP2D6LMNAMAPTHTR1A
Chlorpromazine SCHEMBL27607834 0.97 CYP1A2 (0.97) CYP1A2CYP2D6LMNAMAPTHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9413 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3194027-B1 COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS SOUND PHARMACEUTICALS INCORPORATED (US) 2026-02-11 EP claimed
US-20250367212-A1 PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES MATSUMOTO SHINICHI (JP) 2025-12-04 US claimed
EP-3060043-B1 PESTICIDAL COMPOSITIONS AND RELATED METHODS CORTEVA AGRISCIENCE LLC (US) 2025-11-26 EP claimed
EP-3578542-B1 COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO CORTEVA AGRISCIENCE LLC (US) 2025-11-12 EP claimed
US-20250319073-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON’S DISEASE AND HTT PROTEINOPATHIES STEALTH BIOTHERAPEUTICS INC. (US) 2025-10-16 US claimed
EP-3578543-B1 COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO CORTEVA AGRISCIENCE LLC (US) 2025-08-20 EP claimed
CN-115963188-B Construction method for realizing retention time automatic correction system for detected ion pair group of liquid phase mass spectrum based on labeling system 中精普康(北京)医药科技有限公司 2025-05-30 CN claimed
EP-3578541-B1 COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY, AND PROCESSES RELATED THERETO CORTEVA AGRISCIENCE LLC (US) 2025-05-28 EP claimed
CN-120051271-A Methods for treating infectious diseases 欣扬生医股份有限公司 2025-05-27 CN claimed
CN-120044146-A Method for detecting antipsychotic drugs and metabolites thereof in sample and kit thereof 瑞莱谱(杭州)医疗科技有限公司 2025-05-27 CN claimed
EP-0580776-A1 USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-02-02 EP claimed
CN-1072863-A Be used to improve the dermal osmosis system of the reinforcement of medicine localized delivery RICHARDSON VICKS INC (US) 1993-06-09 CN claimed
CN-1072602-A Improve the enhanced dermal osmosis system of the local conveying of medicine RICHARDSON VICKS INC (US) 1993-06-02 CN claimed
WO-1993007902-A1 ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS RICHARDSON-VICKS, INC. (US) 1993-04-29 WO claimed
WO-1993007903-A1 ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS RICHARDSON-VICKS, INC. (US) 1993-04-29 WO claimed
WO-1992018127-A1 USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-10-29 WO claimed
EP-0180364-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES RECKITT AND COLMAN PRODUCTS LIMITED (GB) 1990-03-07 EP claimed
EP-0123157-B1 MEDICAMENTS AND/OR FOODSTUFF CONCENTRATES WITH AN ANTI-BACTERIAL ACTIVITY EGIS GYOGYSZERGYAR (HU) 1987-06-24 EP claimed
EP-0189861-A2 Percutaneous absorption accelerator for ionic water-soluble medicine SHOWA DENKO KABUSHIKI KAISHA (JP) 1986-08-06 EP claimed
EP-0180364-A2 Pharmaceutical compositions containing phenothiazines RECKITT AND COLMAN PRODUCTS LIMITED (GB) 1986-05-07 EP claimed